Evidence map›Paper›PMID 40151114›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Fuzheng Xuanfei Huashi prescription suppresses inflammation in lipopolysaccharide-induced lung injury in mice toll-like recptor 4/nuclear transcription factor κB and cyclooxygenase-2/prostaglandin E2 pathway.

Huang Haiyang, Zhu Shumin, Zhong Shaowen, Liu Ying, Hou Shaozhen, Gao Jie, O U Jianzhao, Dong Mingguo, Ning Weimin

Abstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huang HaiyangInstitute of Traditional Chinese Medicine, Dongguan Hospital of Traditional Chinese Medicine, Dongguan 523000, China.
Zhu ShuminDepartment of Traditional Chinese Medicine, Guangdong Food and Drug Vocational College, Guangzhou 510520, China.
Zhong ShaowenSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Liu YingSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Hou ShaozhenSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Gao JieSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
O U JianzhaoInstitute of Traditional Chinese Medicine, Dongguan Hospital of Traditional Chinese Medicine, Dongguan 523000, China.
Dong MingguoInstitute of Traditional Chinese Medicine, Dongguan Hospital of Traditional Chinese Medicine, Dongguan 523000, China.
Ning WeiminInstitute of Traditional Chinese Medicine, Dongguan Hospital of Traditional Chinese Medicine, Dongguan 523000, China.

Funding

Emergency Corona Virus Disease 2019 (COVID-19) Response Project of Dongguan: Clinical Efficacy Observation and Mechanism Study of Fuzheng Xuanfei Huashi Formula in the Treatment of COVID-19 Based on the Lingnan Theory of Epidemic Diseases 202071715002124Guangdong Basic and Applied Basic Research Foundation: Development and Industrialization of Traditional Chinese Medicine Classic and Famous Prescription Compound Formulations 2021ZD006National Natural Science Foundation of China: Study on the Mechanism of Lung Inflammatory Injury Induced by Gut-derived Lipopolysaccharide and Skatole in Spleen Deficiency Animals based on Pulmonary Alveolus Macrophage Heterogeneity 82274381
6 · The paper itself

Abstract

objectiveTo determine the effect of Traditional Chinese Medicine (TCM) Fuzheng Xuanfei Huashi prescription (, FZXF) on lipopolysaccharide (LPS)-induced pneumonia in mice and identify the mechanism of FZXF in the treatment of LPS-induced lung inflammation.

methodsThe pneumonia model was established by intraperitoneal injection of 5 mg/kg LPS in mice. Cytokines were detected by enzyme-linked immune-osorbent assay (ELISA), macrophages in lung tissue were determined by immunofluorescence, and pathway-related data were determined by quantitative real-time polymerase chain reaction (qPCR) and Western blot.

resultsThe liver, thymus, and spleen index values and the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) obviously increased in LPS-treated mice. FZXF decreased the white blood cell count and reduced the increase in the lung wet weight/dry weight ratio caused by LPS. The hematoxylin-eosin staining result showed that FZXF could maintain the integrity of lung tissue structure, alleviate interstitial oedema and alveolar wall thickening, and reduce inflammatory cell infiltration. Moreover, FZXF markedly reduced the expression of proinflammatory cytokines. FZXF also significantly reduced LPS-induced malondialdehyde production and increased superoxide dismutase level in the lung. By immunofluorescence, we found that FZXF could reduce macrophage infiltration. The mRNA expression levels of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), toll-like receptor 4 (TLR4) and nuclear transcription factor κB (NF-κB) in the lung tissue of mice were decreased by treatment with FZXF. In addition, FZXF inhibited the protein expression of TLR4, p-p65 and COX-2. These results indicated that FZXF could inhibit the inflammatory response of LPS induced cytokine storm in mice through TLR4/NF-κB and COX-2/PGE2 signaling pathway.

conclusionThese findings were suggested that FZXF prescription suppresses inflammation in LPS-induced pneumonia in mice

Indexed as

Cyclooxygenase 2DinoprostoneDrugs, Chinese HerbalLung InjuryNF-kappa BToll-Like Receptor 4AnimalsHumansLipopolysaccharidesMaleMiceSignal TransductionCyclooxygenase 2DinoprostoneDrugs, Chinese HerbalLipopolysaccharidesNF-kappa BToll-Like Receptor 4cyclooxygenase 2dinoprostoneFuzheng Xuanfei Huashi prescriptionlipopolysaccharidesNF-kappa Bpneumoniasignal transductiontoll-like receptor 4

Identifiers

PMID40151114
PMCPMC11955761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.